No quarterly revenue total was found in NUVECTIS PHARMA, INC.'s SEC filings.
Nuvectis Pharma, Inc. (NVCT) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-30.07M
-303.0% vs year-ago quarter
Operating cash flow
$-25.28M
-462.5% vs year-ago quarter
Free cash flow
—
EPS
$-1.02
-131.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
34.39M
+34.3% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NVCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Lee, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1875558
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$31.0M | -$7.2M | -$6.3M | -$7.6M | -$7.8M |
| Net income | -$30.1M | -$7.0M | -$6.0M | -$7.3M | -$7.5M |
| Diluted EPS | -$1.02 | -$0.30 | -$0.26 | -$0.32 | -$0.44 |
| Operating cash flow | -$25.3M | -$4.5M | -$6.5M | -$4.0M | -$4.5M |
| Total assets | $140.8M | $22.4M | $25.4M | $31.7M | $35.6M |
| Total liabilities | $14.2M | $13.3M | $11.2M | $13.3M | $11.6M |
| Stockholders' equity | $126.6M | $9.1M | $14.2M | $18.4M | $24.0M |
| Cash and investments | $140.7M | $22.2M | $25.1M | $31.6M | $35.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 21, 2026 | Jul 20, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 30, 2026 | Jun 29, 2026 |
All 275 Nuvectis Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.